# Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2mut breast tumors

## TL;DR

The study tested combining PARP and AKT inhibitors to stop early breast tumor growth in mice with BRCA1/2 mutations, finding the combo can intercept but not prevent tumors.

## Contribution

Demonstrates that combining PARP and AKT inhibitors intercepts but does not prevent BRCA1/2-related breast tumors in a mouse model.

## Key findings

- PARP inhibitor alone did not prevent tumor development in the mouse model.
- Combining PARP and AKT inhibitors intercepted existing tumors but did not stop new tumors from forming.
- The PARP/AKT inhibition combination is effective for treating but not preventing BRCA1/2-related breast cancer.

## Abstract

We utilized the K14-Cre Brca1f/fTp53f/f mouse model to investigate whether a pulse of PARP inhibitor (PARPi) ± an AKT inhibitor (AKTi) can prevent Brca1-related breast cancer. PARPi alone did not intercept or prevent tumor development. PARPi+AKTi intercepted tumors but did not prevent new tumors. These data confirm the efficacy of a PARPi and an inhibitor of PI3K signaling in treating BRCA1/2-related tumors, but this combination is not sufficient to prevent carcinogenesis.